XPH — SPDR S&P Pharmaceuticals ETF

—
PCX · Health Care · Developed Markets · CIK ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").
No quarterly fundamentals indexed for this ticker.

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $57.00 · spot: $66.09 · call volume: 48 · put volume: 12

News headlines (Yahoo Finance, 1h cache)

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
2026-08-07 10:20 · Yahoo
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
2026-08-06 10:20 · Yahoo
8 ETF Winners in the ‘Pay Me Now’ Trade
2026-07-31 18:16 · Yahoo
Healthcare ETFs Are Looking Up: Here's Why
2026-08-19 13:00 · Yahoo
These 5 Undervalued ETFs Could Be Bargains Right Now
2026-02-26 12:55 · Yahoo
XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning
2026-02-18 16:58 · Yahoo
Biopharma 2026 outlook: Keep an eye out for M&A
2025-12-24 11:30 · Yahoo
3 Undervalued ETFs to Buy Before 2026
2025-12-10 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.